Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at the DZNE and Charité – Universitätsmedizin Berlin have now discovered how the cortisone compound influences the impaired inflammatory response and which patients benefit from it. Their method uses so-called single-cell analyses and raises hopes for a precise prediction tool for other therapies and diseases as well. The findings have been published in the scientific journal “Cell”.